scispace - formally typeset
Search or ask a question
Journal ArticleDOI

6-Substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid derivatives in a new approach of the treatment of cancer cell invasion and metastasis

TL;DR: Novel 6-substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid derivatives were synthesized and their potency in reducing the invasive behaviour of HT 1080 fibrosarcoma cells was evaluated.
About: This article is published in European Journal of Medicinal Chemistry.The article was published on 2008-12-01 and is currently open access. It has received 48 citations till now. The article focuses on the topics: Aryl & Thioester.

Summary (2 min read)

1. Introduction

  • One of the most difficult problems arising during cancer therapy is the occurrence of cancer cell invasion responsible for the spread of tumour cells throughout the body.
  • Indeed, many efforts are now focussed on the search of compounds interfering with the cancer cell invasion process and expressing antiangiogenic properties [1].
  • The authors recently reported that two synthetic 6-substituted coumarin-3-carboxylic acid derivatives, 3- chlorophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate (1) and 3-bromophenyl 6-acetoxymethyl2-oxo-2H-1-benzopyran-3-carboxylate (2) (Fig. 1), expressed a marked potency in inhibiting cancer cell invasion in vitro and tumour growth in vivo [10].
  • Particular attention was paid to the replacement of the oxygen atom included in the exocyclic ester function in the 3-position by a sulphur atom or by a nitrogen atom with or without a methyl group.
  • The importance of the nature and the size of the substituent in the 6-position was also examined.

2. Chemistry

  • Scheme 1 illustrates the synthetic pathway giving access to the coumarinic derivatives characterised by the introduction of a thioester function or an amide function in the 3-position.
  • Starting from 11, acylation, with the appropriate anhydride, of the exocyclic OH function located on the hydroxymethyl group in the 6-position led to the acid esters 17 (Scheme 2).
  • Examples of coumarin derivatives with a nitro group in the 6-position were obtained according to Scheme 3.
  • Compounds 25 previously described [23] reacted with hexamethylenetetramine to give the hexaminium salts 26.

3. Results and discussion

  • The new synthetic coumarins were examined in a 'Boyden chamber' invasion assay using HT 1080 fibrosarcoma cells in order to determine their potency in reducing the invasive behaviour of tumour cells [10].
  • Results were compared to those observed with a reference compound, GI 129471 (29, Fig. 3), a well-known broad-spectrum hydroxamate-type MMP inhibitor, used at 1 µM concentration, previously reported to be active in this model [10], and also compared to those obtained with the active coumarin derivatives 1 and 2 at three different concentrations: 0.1, 1 and 10 µM.
  • As previously reported, the bromo-substituted coumarin 2 giving 78% inhibition of cell invasion at 1 µM concentration was found to be more potent than the reference compound GI 129471, whereas the corresponding chloro-substituted analogue 1 was also active (51% inhibition of cell invasion at 1 µM) but less potent than the two formers [10].
  • Such an effect could be explained by the fact that amides such as 15a may adopt a stable conformation in which a strong hydrogen bond interaction is established between the NH group and the lactonic carbonyl oxygen.
  • Thus, except in the case of an iodine atom, another halogen atom on the phenyl ring didn't improve the activity.

4. Conclusion

  • The present work aimed at describing new examples of coumarin-3-carboxylic acid derivatives structurally related to lead coumarins 1 and 2 expressing anti-invasive activity in vitro and anti-tumoral effect in vivo.
  • Among the different chemical modifications examined, the replacement of the ester function in the 6-position of 1 and 2 by an amide function was allowed without loss of potency in the 'Boyden chamber' chemoinvasion assay with HT 1080 fibrosarcoma cells.
  • By contrast, an aryl ester function in the 3-position was strongly recommended since its replacement by a thioester or an amide function was responsible for a significant decrease of the antiinvasive activity.
  • The increase of the size of the alkyl chain located on the acyloxymethyl moiety in the 6-position reduced the anti-invasive activity, although a short branched chain such as an isopropyl or a tert-butyl chain was allowed without markedly reducing the activity in the chemoinvasion assay.

Did you find this useful? Give us your feedback

Citations
More filters
Journal ArticleDOI
TL;DR: The whole range of medicinal chemistry in the current developments of coumarin compounds as anticoagulant, antineurodegenerative, anticancer, antioxidative, antibacterial, antifungal, antiviral, antiparasitic, antiinflammatory and analgesic, antidiabetic, antidepressive and other bioactive agents as well as supramolecular medicinal drugs, diagnostic agents and pathologic probes, and biological stains are presented.
Abstract: Coumarin compounds represent an important type of naturally occurring and synthetic oxygen-containing heterocycles with typical benzopyrone framework. This type of special benzopyrone structure enables its derivatives readily interact with a diversity of enzymes and receptors in organisms through weak bond interactions, thereby exhibit wide potentiality as medicinal drugs. So far, some coumarin-based drugs such as anticoagulant and antineurodegenerative agents have been extensively used in clinic. Coumarin-containing supramolecular medicinal agents as a new increasing expansion of supramolecular chemistry in pharmaceutical science have also been actively investigated in recent years. Coumarin-derived artificial ion receptors, fluorescent probes and biological stains are growing quickly and have a variety of potential applications in monitoring timely enzyme activity, complex biological events as well as accurate pharmacological and pharmacokinetic properties. This review provides a systematic summary and insight of the whole range of medicinal chemistry in the current developments of coumarin compounds as anticoagulant, antineurodegenerative, anticancer, antioxidative, antibacterial, antifungal, antiviral, antiparasitic, antiinflammatory and analgesic, antidiabetic, antidepressive and other bioactive agents as well as supramolecular medicinal drugs, diagnostic agents and pathologic probes, and biological stains. Some rational design strategies, structure-activity relationships and action mechanisms are discussed. The perspectives of the future development of coumarinbased medicinal chemistry are also presented.

369 citations


Cites background from "6-Substituted 2-oxo-2H-1-benzopyran..."

  • ...Apart from the above mentioned cancers, coumarin compounds still exert influential potency against other cancers [124-126]....

    [...]

Journal ArticleDOI
TL;DR: The current developments of coumarin-based anticancer agents are covered and the structure-activity relationship of the most potent compounds are discussed.

352 citations

Journal ArticleDOI
Longhuo Wu1, Xiao Wang, William Xu, Farzin Farzaneh, Ruian Xu 
TL;DR: This review will focus on recent advances in molecular and cellular mechanisms of coumarin action involved with the relationship between structure and activity.
Abstract: Coumarins are of many different structures. They constitute an important class of pharmacological agents possessing a range of different physiological activities including anti-cancer, anti-oxidant, anti- inflammation, anti-HIV, anti-coagulant, anti-bacterial, analgesic and comparative immune-modulation. Recently, coumarins have attracted intense research interest. Of great interest is the possibility that this class of molecules could be a source of drugs for the therapy of several diseases. These include recent insights into inhibiting cell proliferation by interfering with mitotic spindle microtubule function, decrease Matrix Metalloproteinase (MMP) activity, block the cell cycle in the S or G2/M phases to interfere with processes of cell division, suppress O2(-) generation in leukocytes, inhibit different protein kinases, modulate the signalings, induce carcinogen-detoxifying enzymes glutathione S-transferases (GSTs) and/or NAD(P)H quinine oxidoreductase (NQO1), suppress the phosphorylation of Akt/PKB as a mechanism inhibiting inflammation, progress in structure modification to increase in anti-fungal action, to broaden against bacteria spectrum, to enhance inhibiting activities of nitric oxide synthase (NOS) and cyclooxygenase (COX), to strengthen anti-oxidant activity and to exhibite a much higher cytotoxicity against human umbilical vein endothelial cell (HUVEC). With fewer non-hemorrhagic side effects than the indanedione derivatives, they can be applied as an oral anticoagulant commonly for preventing venous thromboembolism following orthopedic surgery, recurrent myocardial infarction and the treatment of systemic embolism in atrial fibrillation, together with the significant advances in the basis of drug action. It is therefore useful to build up some correlations with the data available in order to better explore the molecular and cellular mechanism of coumarin action in the treatment of diseases. This review will focus on recent advances in molecular and cellular mechanisms of coumarin action involved with the relationship between structure and activity.

217 citations

Journal ArticleDOI
TL;DR: The occurence, synthesis and specific biological activities of various coumarin derivatives are described for the discovery and development of new synthetic strategies that could help in structure–activity relationship (SAR) studies.
Abstract: Coumarins are oxygen-containing molecules with specific benzopyrone nucleus. Different coumarins are identified as antineurodegeneratives, anticoagulants, antioxidants, antimicrobials, anticancers, antivirals, antidiabetics, antidepressants, supramoleculars, antiparasitics, anti-inflammatory, analgesics, biological stains, pathological probes and diagnostics. Coumarins have received more attention as compared to 1-azacoumarins. Many attempts have been made for the comparison of both the systems at different stages to discover novel synthetic methodologies, reactivity strategies and biological activities. Translation of current knowledge into novel potent lead compounds and repositioning of well-known compounds for the treatment of different acute and chronic diseases are the current challenges of coumarins. This review article focusses on the occurence, synthesis and specific biological activities of various coumarin derivatives. Some novel research approaches are also described for the discovery and development of new synthetic strategies that could help in structure–activity relationship (SAR) studies. Cellular and molecular mechanisms of coumarins involved in SAR studies are also described.

99 citations


Cites background from "6-Substituted 2-oxo-2H-1-benzopyran..."

  • ..., 2008; Henry and Yen, 2008), anticancer (Win et al., 2008; Isabelle et al., 2008), anticonvulsant (Fatma et al....

    [...]

  • ...…(Kalkhambkar et al., 2008; Grimm et al., 2006), antiplatelet aggregation (Juan et al., 2008; Henry and Yen, 2008), anticancer (Win et al., 2008; Isabelle et al., 2008), anticonvulsant (Fatma et al., 2008), comparative immunomodulatory (Cherng et al., 2008) and analgesic (Hu et al., 2008;…...

    [...]

Journal ArticleDOI
TL;DR: In this article, the carbon-carbon (C-C) bond forms the backbone of nearly every organic molecule and lies at the heart of the chemical sciences, and the most effective way to save energy is to develop strategies/protocols that are capable enough to carry out the transformations at ambient temperature and pressure.
Abstract: The carbon–carbon (C–C) bond forms the ‘backbone’ of nearly every organic molecule, and lies at the heart of the chemical sciences! This transformation has always been one of the most useful and fundamental reactions in the development of organic chemistry. Currently, the concept of ‘green chemistry’ is globally acclaimed and has already advanced quite significantly to emerge as a distinct branch of chemical sciences. Among the principles of ‘green chemistry’, one principle is dedicated to the “design of energy efficiency” – that is to develop synthetic strategies that require less/minimum amounts of energy to carry out a specific reaction with optimum productivity. And the most effective way to save energy is to develop strategies/protocols that are capable enough to carry out the transformations at ambient temperature and pressure! As part of the on-going developments in green synthetic strategies, designing for reactions under ambient conditions coupled with other green aspects is, thus, an area of current choice. This review is aimed at offering an up-to-date development on the design of carbon–carbon bond forming protocols to access a wide variety of organic molecules of topical significance under ambient conditions. The account highlights the brilliant applications of reaction conditions such as the use of solvents or no solvent, catalysts or no catalyst, and the use of green tools like ball-milling, ultrasonication and visible light in achieving the goal!

68 citations

References
More filters
Journal ArticleDOI
TL;DR: The development of sunitinib, particularly in acute myeloid leukemia, imatinib-resistant gastrointestinal stromal tumors and renal cell cancer, is discussed, as well as its potential future development in combination therapy with other agents and in other malignancies.
Abstract: The advent of targeted therapies has allowed treatment to be directed at signaling pathways integral to tumor growth and survival. Sunitinib (SU11248, sunitinib malate; Pfizer Inc., New York, NY, USA) is a novel oral small-molecule multitargeted receptor tyrosine kinase inhibitor that has demonstrated direct antitumor activity and antiangiogenic action. It targets the vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR), stem-cell factor receptor and Fms-like tyrosine kinase receptor 3 receptor tyrosine-kinases. In January 2006, sunitinib malate was granted approval by the U.S. Food and Drug Administration for the treatment of gastrointestinal stromal tumor after disease progression on, or intolerance to, imatinib mesylate, as well as for the treatment of metastatic renal cell cancer. This review will discuss the development of sunitinib, particularly in acute myeloid leukemia, imatinib-resistant gastrointestinal stromal tumors and renal cell cancer. The review will also discuss ongoing trials with sunitinib in other malignancies such as neuroendocrine tumors and breast cancer, as well as its potential future development in combination therapy with other agents and in other malignancies.

65 citations

Journal ArticleDOI
TL;DR: This study shows the participation of p38 MAP kinase in 6-nitro-7-hydroxycoumarin induced apoptosis of A-498 cells and suggests that targeting of p 38 may represent a novel mechanism to inhibit renal cell carcinoma and that coumarin type drugs require further investigation as potential anticancer agents directed against renal cell cancer.

65 citations

Journal ArticleDOI
TL;DR: Some of the advances in inhibitor design and the mechanisms of action for the aforementioned factors (targets) involved in angiogenesis regulation are described and it is revealed that a diaryl group separated by various connecting modules is one of the most common features for antiangiogenesis drug design.
Abstract: The initiation, growth, and development of new blood vessels through angiogenesis are essential for tumor growth. Tumor masses require access to blood vessels for a sufficient supply of oxygen and nutrients to maintain growth and metastasis. Inhibiting tumor blood vessel formation as proposed by Judah Folkman in the early 1970s, therefore, offers promising therapeutic approaches for treating tumor afflicted patients. The blood vessel growth in normal tissues is regulated though a delicate and complex balance between the collective action of proangiogenic factors (e.g., vascular endothelial growth factor, VEGF) and the collective action of angiogenic inhibitors (e.g., thrombospondin-1). In pathological angiogenesis, the angiogenic switch is shifted toward the proangiogenic factors, and if the imbalance continues, irregular tumor vessel growth is the result. Despite intense research, the mechanism of the angiogenic switch is not fully understood. Many factors, however, have been shown to be involved in regulating the equilibrium between angiogenic stimulants and inhibitors. VEGFR tyrosine kinase, methionine aminopeptidase-2 (MetAP-2), p53, tubulin, cyclooxygenase-2 (COX-2), and matrix metalloproteinases (MMPs) all directly and/or indirectly influence the angiogenic switch. This review will describe some of the advances in inhibitor design and the mechanisms of action for the aforementioned factors (targets) involved in angiogenesis regulation. Our discussion reveals that a diaryl group separated by various connecting modules is one of the most common features for antiangiogenesis drug design. This idea has been a working pharmacophore hypothesis for our own antiangiogenic drug design endeavors over the years. The recent advances of combination therapy (angiogenesis inhibitors with other chemotherapy/radiation) are also discussed.

59 citations

Journal Article
TL;DR: In the present studies, using Matrigel in in vivo angiogenesis assays, Linomide treatment at a dose of 25 mg/kg/day was able to inhibit by approximately 60% the incidence of N-methylnitrosourea and approximately 50% of 7-12-dimethyl-benz(a)anthracine-induced mammary carcinogenesis in female rats.
Abstract: There are two distinct phases during prostatic carcinogenesis with regard to tumor blood vessel development. During the first or prevascular phase, which may persist for years, cells that have undergone some but not all of the transformation steps undergo a limited amount of net growth, producing premalignant prostatic intraepithelial neoplastic (PIN) lesions. Most of these PIN lesions do not continue net growth and do not progress to produce histologically detectable cancer. Even the PIN lesions that do progress to cancer remain of limited virulence unless they undergo conversion to the second or angiogenic phase. Once this angiogenic phase is reached, new blood vessel development is greatly enhanced within the cancer. It is this enhanced tumor angiogenesis which allows these cancers both to grow continuously and to metastasize. Thus, inhibition of angiogenesis should be an effective chemopreventive approach for prostatic carcinogenesis. Linomide is a low molecular weight, water-soluble agent with excellent p.o. absorption and bioavailability. We have previously demonstrated that daily p.o. treatment with Linomide has antiangiogenic abilities against a series of rat and human prostatic cancer xenografts growing in vivo . In the present studies, we have demonstrated using Matrigel in in vivo angiogenesis assays that daily p.o. Linomide at 25 mg/kg/day inhibits angiogenesis induced by tumor necrosis factor α, acidic fibroblast growth factor, basic fibroblast growth factor, and vascular endothelial growth factor. Using an N -methylnitrosourea initiation-androgen promotion model, Linomide was given p.o. at a daily dose as high as 25 mg/kg/day for at least 1 year without major toxicity while inhibiting the development of seminal vesicle/prostate cancers in male rats by >50%. Dose-response analysis demonstrated that a Linomide blood level of 50–100 µm is optimal for such chemoprevention. In addition, Linomide treatment at a dose of 25 mg/kg/day was able to inhibit by ∼60% the incidence of N -methylnitrosourea and ∼50% of 7,12-dimethyl-benz( a )anthracine-induced mammary carcinogenesis in female rats.

58 citations

Journal ArticleDOI
TL;DR: The angiogenesis inhibitor bevacizumab (avastin), a humanized anti-vascular endothelial growth factor (VEGF) antibody, showed a survival benefit of 4.7 months in a phase III clinical trial in patients with advanced colorectal cancer when this agent was given in combination with chemotherapy.
Abstract: In the past decade, many angiogenesis inhibitors have been developed for clinical use in oncology. Surgeons, radiotherapists as well as medical oncologists have been investigating with much effort and enthusiasm the translation of these agents from the preclinical setting into treatment strategies of patients. Recently, for the first time in history, the angiogenesis inhibitor bevacizumab (avastin), a humanized anti-vascular endothelial growth factor (VEGF) antibody, showed a survival benefit of 4.7 months in a phase III clinical trial in patients with advanced colorectal cancer when this agent was given in combination with chemotherapy. At the annual meeting of the American Association of Clinical Oncology 2005, similar results of bevacizumab in lung, breast and ovarian cancer clinical trials have been shown. These landmark studies proofed for the first time in the clinical setting that Dr. Folkman back in 1971 was right by proposing: "in order to stop tumor growth, one should attack its blood supply". Nowadays it seems trivial to propose such a hypothesis, at that time it was a very provocative hypothesis and it took more than 30 years to proof this hypothesis in the clinic. Although one may be excited about this major finding, there is no time to relax. The survival benefit of bevacizumab is only about 4 months. Therefore more potent antiangiogenic agents and more active treatment strategies are urgently warranted. Newer angiogenesis inhibitors that are currently in preclinical or early clinical development have shown in preclinical experiments improved antitumor activities. In addition, combinations of biological agents that interfere in multiple biological pathways in cancer growth including chemotherapy, are of major clinical interest as well. The multimodality approach in which surgeons, radiotherapists and medical oncologists collaborate needs to be explored as well. In a variety of cancer types, like breast colon and lung cancer, these specialists should design multimodality strategies based on current standard treatment in which they incorporate angiogenesis inhibitors in the right time frame of surgery and radiotherapy. In this review we will bring you up to date on the clinical development of angiogenesis inhibitors and we will summarize the multimodality strategies that are under development.

53 citations

Frequently Asked Questions (1)
Q1. What are the contributions in "6-substituted 2-oxo-2h-1-benzopyran-3-carboxylic acid derivatives in a new approach of the treatment of cancer cell invasion and metastasis" ?

This work confirms the interest of aryl esters of 6-substituted coumarin-3-carboxylic acids as potential new anticancer agents.